{
    "root": "35cd2705-eb39-aaaa-e063-6294a90a66c9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "FOTIVDA",
    "value": "20250523",
    "ingredients": [
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TIVOZANIB HYDROCHLORIDE",
            "code": "8A9H4VK35Z"
        }
    ],
    "indications": "fotivda indicated treatment adult patients relapsed refractory advanced renal cell carcinoma ( rcc ) following two prior systemic therapies .",
    "contraindications": "recommended dose : 1.34 mg daily without food 21 days treatment followed 7 days treatment ( 28-day cycle ) disease progression unacceptable toxicity . ( 2.1 ) dose interruptions and/or dose reduction may needed manage . ( 2.2 ) patients moderate hepatic impairment , reduce dose 0.89 mg 21 days treatment followed 7 days treatment ( 28-day cycle ) . ( 2.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.",
    "contraindications_original": "Recommended Dose: 1.34 mg once daily with or without food for 21 days on treatment followed by 7 days off treatment (28-day cycle) until disease progression or unacceptable toxicity. ( 2.1 ) Dose interruptions and/or dose reduction may be needed to manage adverse reactions. ( 2.2 ) For patients with moderate hepatic impairment, reduce the dose to 0.89 mg for 21 days on treatment followed by 7 days off treatment (28-day cycle). ( 2.3 )",
    "adverseReactions_original": "None."
}